#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Multi-echo fMRI, resting-state connectivity, and high psychometric schizotypy Disrupted striatal functional connectivity is proposed to play a critical role in the development of psychotic symptoms.
1-1	0-10	Multi-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-2	11-15	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
1-3	16-17	,	_
1-4	18-31	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-5	32-44	connectivity	_
1-6	45-46	,	_
1-7	47-50	and	_
1-8	51-55	high	_
1-9	56-68	psychometric	_
1-10	69-79	schizotypy	_
1-11	80-89	Disrupted	_
1-12	90-98	striatal	_
1-13	99-109	functional	_
1-14	110-122	connectivity	_
1-15	123-125	is	_
1-16	126-134	proposed	_
1-17	135-137	to	_
1-18	138-142	play	_
1-19	143-144	a	_
1-20	145-153	critical	_
1-21	154-158	role	_
1-22	159-161	in	_
1-23	162-165	the	_
1-24	166-177	development	_
1-25	178-180	of	_
1-26	181-190	psychotic	_
1-27	191-199	symptoms	_
1-28	200-201	.	_

Text=Previous resting-state functional magnetic resonance imaging (rs-fMRI) studies typically reported disrupted striatal connectivity in patients with psychosis and in individuals at clinical and genetic high risk of the disorder relative to healthy controls.
2-1	202-210	Previous	_
2-2	211-224	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-3	225-235	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-4	236-244	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-5	245-254	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-6	255-262	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-7	263-264	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-8	265-272	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-9	273-274	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-10	275-282	studies	_
2-11	283-292	typically	_
2-12	293-301	reported	_
2-13	302-311	disrupted	_
2-14	312-320	striatal	_
2-15	321-333	connectivity	_
2-16	334-336	in	_
2-17	337-345	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-18	346-350	with	_
2-19	351-360	psychosis	_
2-20	361-364	and	_
2-21	365-367	in	_
2-22	368-379	individuals	_
2-23	380-382	at	_
2-24	383-391	clinical	_
2-25	392-395	and	_
2-26	396-403	genetic	_
2-27	404-408	high	_
2-28	409-413	risk	_
2-29	414-416	of	_
2-30	417-420	the	_
2-31	421-429	disorder	_
2-32	430-438	relative	_
2-33	439-441	to	_
2-34	442-449	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-35	450-458	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-36	459-460	.	_

Text=This has not been widely studied in healthy individuals with subclinical psychotic-like experiences (schizotypy).
3-1	461-465	This	_
3-2	466-469	has	_
3-3	470-473	not	_
3-4	474-478	been	_
3-5	479-485	widely	_
3-6	486-493	studied	_
3-7	494-496	in	_
3-8	497-504	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-9	505-516	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-10	517-521	with	_
3-11	522-533	subclinical	_
3-12	534-548	psychotic-like	_
3-13	549-560	experiences	_
3-14	561-562	(	_
3-15	563-573	schizotypy	_
3-16	574-575	)	_
3-17	576-577	.	_

Text=Here we applied the emerging technology of multi-echo rs-fMRI to examine corticostriatal connectivity in this group, which is thought to drastically maximize physiological noise removal and increase BOLD contrast-to-noise ratio.
4-1	578-582	Here	_
4-2	583-585	we	_
4-3	586-593	applied	_
4-4	594-597	the	_
4-5	598-606	emerging	_
4-6	607-617	technology	_
4-7	618-620	of	_
4-8	621-631	multi-echo	_
4-9	632-639	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-10	640-642	to	_
4-11	643-650	examine	_
4-12	651-666	corticostriatal	_
4-13	667-679	connectivity	_
4-14	680-682	in	_
4-15	683-687	this	_
4-16	688-693	group	_
4-17	694-695	,	_
4-18	696-701	which	_
4-19	702-704	is	_
4-20	705-712	thought	_
4-21	713-715	to	_
4-22	716-727	drastically	_
4-23	728-736	maximize	_
4-24	737-750	physiological	_
4-25	751-756	noise	_
4-26	757-764	removal	_
4-27	765-768	and	_
4-28	769-777	increase	_
4-29	778-782	BOLD	_
4-30	783-800	contrast-to-noise	_
4-31	801-806	ratio	_
4-32	807-808	.	_

Text=Multi-echo rs-fMRI data (echo times, 12, 28, 44, 60 ms) were acquired from healthy individuals with low (LS, n = 20) and high (HS, n = 19) positive schizotypy as determined with the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE).
5-1	809-819	Multi-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-2	820-827	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-3	828-832	data	_
5-4	833-834	(	_
5-5	835-839	echo	_
5-6	840-845	times	_
5-7	846-847	,	_
5-8	848-850	12	_
5-9	851-852	,	_
5-10	853-855	28	_
5-11	856-857	,	_
5-12	858-860	44	_
5-13	861-862	,	_
5-14	863-865	60	_
5-15	866-868	ms	_
5-16	869-870	)	_
5-17	871-875	were	_
5-18	876-884	acquired	_
5-19	885-889	from	_
5-20	890-897	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-21	898-909	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-22	910-914	with	_
5-23	915-918	low	_
5-24	919-920	(	_
5-25	921-923	LS	_
5-26	924-925	,	_
5-27	926-927	n	_
5-28	928-929	=	_
5-29	930-932	20	_
5-30	933-934	)	_
5-31	935-938	and	_
5-32	939-943	high	_
5-33	944-945	(	_
5-34	946-948	HS	_
5-35	949-950	,	_
5-36	951-952	n	_
5-37	953-954	=	_
5-38	955-957	19	_
5-39	958-959	)	_
5-40	960-968	positive	_
5-41	969-979	schizotypy	_
5-42	980-982	as	_
5-43	983-993	determined	_
5-44	994-998	with	_
5-45	999-1002	the	_
5-46	1003-1019	Oxford-Liverpool	_
5-47	1020-1029	Inventory	_
5-48	1030-1032	of	_
5-49	1033-1041	Feelings	_
5-50	1042-1045	and	_
5-51	1046-1057	Experiences	_
5-52	1058-1059	(	_
5-53	1060-1066	O-LIFE	_
5-54	1067-1068	)	_
5-55	1069-1070	.	_

Text=After preprocessing to ensure optimal contrast and removal of non-BOLD signal components, whole-brain functional connectivity from six striatal seeds was compared between the HS and LS groups.
6-1	1071-1076	After	_
6-2	1077-1090	preprocessing	_
6-3	1091-1093	to	_
6-4	1094-1100	ensure	_
6-5	1101-1108	optimal	_
6-6	1109-1117	contrast	_
6-7	1118-1121	and	_
6-8	1122-1129	removal	_
6-9	1130-1132	of	_
6-10	1133-1141	non-BOLD	_
6-11	1142-1148	signal	_
6-12	1149-1159	components	_
6-13	1160-1161	,	_
6-14	1162-1173	whole-brain	_
6-15	1174-1184	functional	_
6-16	1185-1197	connectivity	_
6-17	1198-1202	from	_
6-18	1203-1206	six	_
6-19	1207-1215	striatal	_
6-20	1216-1221	seeds	_
6-21	1222-1225	was	_
6-22	1226-1234	compared	_
6-23	1235-1242	between	_
6-24	1243-1246	the	_
6-25	1247-1249	HS	_
6-26	1250-1253	and	_
6-27	1254-1256	LS	_
6-28	1257-1263	groups	_
6-29	1264-1265	.	_

Text=Effects were considered significant at cluster-level p <.05 family-wise error correction.
7-1	1266-1273	Effects	_
7-2	1274-1278	were	_
7-3	1279-1289	considered	_
7-4	1290-1301	significant	_
7-5	1302-1304	at	_
7-6	1305-1318	cluster-level	_
7-7	1319-1320	p	_
7-8	1321-1322	<	_
7-9	1323-1326	.05	_
7-10	1327-1338	family-wise	_
7-11	1339-1344	error	_
7-12	1345-1355	correction	_
7-13	1356-1357	.	_

Text=Compared to LS, HS subjects showed lower rs-fMRI connectivity between ventromedial prefrontal regions and ventral striatal regions.
8-1	1358-1366	Compared	_
8-2	1367-1369	to	_
8-3	1370-1372	LS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-4	1373-1374	,	_
8-5	1375-1377	HS	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-6	1378-1386	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-7	1387-1393	showed	_
8-8	1394-1399	lower	_
8-9	1400-1407	rs-fMRI	_
8-10	1408-1420	connectivity	_
8-11	1421-1428	between	_
8-12	1429-1441	ventromedial	_
8-13	1442-1452	prefrontal	_
8-14	1453-1460	regions	_
8-15	1461-1464	and	_
8-16	1465-1472	ventral	_
8-17	1473-1481	striatal	_
8-18	1482-1489	regions	_
8-19	1490-1491	.	_

Text=Lower connectivity was also observed between the dorsal putamen and the hippocampus, occipital regions, as well as the cerebellum.
9-1	1492-1497	Lower	_
9-2	1498-1510	connectivity	_
9-3	1511-1514	was	_
9-4	1515-1519	also	_
9-5	1520-1528	observed	_
9-6	1529-1536	between	_
9-7	1537-1540	the	_
9-8	1541-1547	dorsal	_
9-9	1548-1555	putamen	_
9-10	1556-1559	and	_
9-11	1560-1563	the	_
9-12	1564-1575	hippocampus	_
9-13	1576-1577	,	_
9-14	1578-1587	occipital	_
9-15	1588-1595	regions	_
9-16	1596-1597	,	_
9-17	1598-1600	as	_
9-18	1601-1605	well	_
9-19	1606-1608	as	_
9-20	1609-1612	the	_
9-21	1613-1623	cerebellum	_
9-22	1624-1625	.	_

Text=These results demonstrate that subclinical positive psychotic-like experiences in healthy individuals are associated with striatal hypoconnectivity as detected using multi-echo rs-fMRI.
10-1	1626-1631	These	_
10-2	1632-1639	results	_
10-3	1640-1651	demonstrate	_
10-4	1652-1656	that	_
10-5	1657-1668	subclinical	_
10-6	1669-1677	positive	_
10-7	1678-1692	psychotic-like	_
10-8	1693-1704	experiences	_
10-9	1705-1707	in	_
10-10	1708-1715	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-11	1716-1727	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-12	1728-1731	are	_
10-13	1732-1742	associated	_
10-14	1743-1747	with	_
10-15	1748-1756	striatal	_
10-16	1757-1773	hypoconnectivity	_
10-17	1774-1776	as	_
10-18	1777-1785	detected	_
10-19	1786-1791	using	_
10-20	1792-1802	multi-echo	_
10-21	1803-1810	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-22	1811-1812	.	_

Text=Further application of this approach may aid in characterizing functional connectivity abnormalities across the extended psychosis phenotype.
11-1	1813-1820	Further	_
11-2	1821-1832	application	_
11-3	1833-1835	of	_
11-4	1836-1840	this	_
11-5	1841-1849	approach	_
11-6	1850-1853	may	_
11-7	1854-1857	aid	_
11-8	1858-1860	in	_
11-9	1861-1875	characterizing	_
11-10	1876-1886	functional	_
11-11	1887-1899	connectivity	_
11-12	1900-1913	abnormalities	_
11-13	1914-1920	across	_
11-14	1921-1924	the	_
11-15	1925-1933	extended	_
11-16	1934-1943	psychosis	_
11-17	1944-1953	phenotype	_
11-18	1954-1955	.	_

Text=Highlights Multi-echo fMRI was used to investigate resting-state connectivity in subjects with low and high psychometric schizotypy (HS).
12-1	1956-1966	Highlights	_
12-2	1967-1977	Multi-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
12-3	1978-1982	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
12-4	1983-1986	was	_
12-5	1987-1991	used	_
12-6	1992-1994	to	_
12-7	1995-2006	investigate	_
12-8	2007-2020	resting-state	_
12-9	2021-2033	connectivity	_
12-10	2034-2036	in	_
12-11	2037-2045	subjects	_
12-12	2046-2050	with	_
12-13	2051-2054	low	_
12-14	2055-2058	and	_
12-15	2059-2063	high	_
12-16	2064-2076	psychometric	_
12-17	2077-2087	schizotypy	_
12-18	2088-2089	(	_
12-19	2090-2092	HS	_
12-20	2093-2094	)	_
12-21	2095-2096	.	_

Text=High schizotypy subjects showed hypoconnectivity between ventral striatum and ventromedial prefrontal cortex.
13-1	2097-2101	High	_
13-2	2102-2112	schizotypy	_
13-3	2113-2121	subjects	_
13-4	2122-2128	showed	_
13-5	2129-2145	hypoconnectivity	_
13-6	2146-2153	between	_
13-7	2154-2161	ventral	_
13-8	2162-2170	striatum	_
13-9	2171-2174	and	_
13-10	2175-2187	ventromedial	_
13-11	2188-2198	prefrontal	_
13-12	2199-2205	cortex	_
13-13	2206-2207	.	_

Text=These subjects also showed hypoconnectivity between dorsal striatum and temporooccipital regions.
14-1	2208-2213	These	_
14-2	2214-2222	subjects	_
14-3	2223-2227	also	_
14-4	2228-2234	showed	_
14-5	2235-2251	hypoconnectivity	_
14-6	2252-2259	between	_
14-7	2260-2266	dorsal	_
14-8	2267-2275	striatum	_
14-9	2276-2279	and	_
14-10	2280-2296	temporooccipital	_
14-11	2297-2304	regions	_
14-12	2305-2306	.	_

Text=Methods and materials Participants Two hundred and fifty potential participants who had responded to online advertising via the Research Volunteer Recruitment Webpage of King's College London were pre-screened using the short version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE).
15-1	2307-2314	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-2	2315-2318	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-3	2319-2328	materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
15-4	2329-2341	Participants	_
15-5	2342-2345	Two	_
15-6	2346-2353	hundred	_
15-7	2354-2357	and	_
15-8	2358-2363	fifty	_
15-9	2364-2373	potential	_
15-10	2374-2386	participants	_
15-11	2387-2390	who	_
15-12	2391-2394	had	_
15-13	2395-2404	responded	_
15-14	2405-2407	to	_
15-15	2408-2414	online	_
15-16	2415-2426	advertising	_
15-17	2427-2430	via	_
15-18	2431-2434	the	_
15-19	2435-2443	Research	_
15-20	2444-2453	Volunteer	_
15-21	2454-2465	Recruitment	_
15-22	2466-2473	Webpage	_
15-23	2474-2476	of	_
15-24	2477-2481	King	_
15-25	2482-2484	's	_
15-26	2485-2492	College	_
15-27	2493-2499	London	_
15-28	2500-2504	were	_
15-29	2505-2517	pre-screened	_
15-30	2518-2523	using	_
15-31	2524-2527	the	_
15-32	2528-2533	short	_
15-33	2534-2541	version	_
15-34	2542-2544	of	_
15-35	2545-2548	the	_
15-36	2549-2565	Oxford-Liverpool	_
15-37	2566-2575	Inventory	_
15-38	2576-2578	of	_
15-39	2579-2587	Feelings	_
15-40	2588-2591	and	_
15-41	2592-2603	Experiences	_
15-42	2604-2605	(	_
15-43	2606-2612	O-LIFE	_
15-44	2613-2614	)	_
15-45	2615-2616	.	_

Text=Subjects were invited to participate in the study if they scored <2 (low positive schizotypy, LS) or> 7 (high positive schizotypy, HS) on the Unusual Experiences subscale of the O-LIFE, as in a previous imaging study in our center.
16-1	2617-2625	Subjects	_
16-2	2626-2630	were	_
16-3	2631-2638	invited	_
16-4	2639-2641	to	_
16-5	2642-2653	participate	_
16-6	2654-2656	in	_
16-7	2657-2660	the	_
16-8	2661-2666	study	_
16-9	2667-2669	if	_
16-10	2670-2674	they	_
16-11	2675-2681	scored	_
16-12	2682-2683	<	_
16-13	2684-2685	2	_
16-14	2686-2687	(	_
16-15	2688-2691	low	_
16-16	2692-2700	positive	_
16-17	2701-2711	schizotypy	_
16-18	2712-2713	,	_
16-19	2714-2716	LS	_
16-20	2717-2718	)	_
16-21	2719-2721	or	_
16-22	2722-2723	>	_
16-23	2724-2725	7	_
16-24	2726-2727	(	_
16-25	2728-2732	high	_
16-26	2733-2741	positive	_
16-27	2742-2752	schizotypy	_
16-28	2753-2754	,	_
16-29	2755-2757	HS	_
16-30	2758-2759	)	_
16-31	2760-2762	on	_
16-32	2763-2766	the	_
16-33	2767-2774	Unusual	_
16-34	2775-2786	Experiences	_
16-35	2787-2795	subscale	_
16-36	2796-2798	of	_
16-37	2799-2802	the	_
16-38	2803-2809	O-LIFE	_
16-39	2810-2811	,	_
16-40	2812-2814	as	_
16-41	2815-2817	in	_
16-42	2818-2819	a	_
16-43	2820-2828	previous	_
16-44	2829-2836	imaging	_
16-45	2837-2842	study	_
16-46	2843-2845	in	_
16-47	2846-2849	our	_
16-48	2850-2856	center	_
16-49	2857-2858	.	_

Text=The UE subscale of the O-LIFE questionnaire reflects positive schizotypy and is associated with positive symptoms in schizophrenia patients.
17-1	2859-2862	The	_
17-2	2863-2865	UE	_
17-3	2866-2874	subscale	_
17-4	2875-2877	of	_
17-5	2878-2881	the	_
17-6	2882-2888	O-LIFE	_
17-7	2889-2902	questionnaire	_
17-8	2903-2911	reflects	_
17-9	2912-2920	positive	_
17-10	2921-2931	schizotypy	_
17-11	2932-2935	and	_
17-12	2936-2938	is	_
17-13	2939-2949	associated	_
17-14	2950-2954	with	_
17-15	2955-2963	positive	_
17-16	2964-2972	symptoms	_
17-17	2973-2975	in	_
17-18	2976-2989	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-19	2990-2998	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-20	2999-3000	.	_

Text=Participants were excluded if they had a history of neurologic/psychiatric disorders as assessed using the Mini International Neuropsychiatric Inventory and the Psychosis Screening Questionnaire (administered by a trained interviewer and reviewed by an experienced neuropsychologist, GM).
18-1	3001-3013	Participants	_
18-2	3014-3018	were	_
18-3	3019-3027	excluded	_
18-4	3028-3030	if	_
18-5	3031-3035	they	_
18-6	3036-3039	had	_
18-7	3040-3041	a	_
18-8	3042-3049	history	_
18-9	3050-3052	of	_
18-10	3053-3075	neurologic/psychiatric	_
18-11	3076-3085	disorders	_
18-12	3086-3088	as	_
18-13	3089-3097	assessed	_
18-14	3098-3103	using	_
18-15	3104-3107	the	_
18-16	3108-3112	Mini	_
18-17	3113-3126	International	_
18-18	3127-3143	Neuropsychiatric	_
18-19	3144-3153	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
18-20	3154-3157	and	_
18-21	3158-3161	the	_
18-22	3162-3171	Psychosis	_
18-23	3172-3181	Screening	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-24	3182-3195	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-25	3196-3197	(	_
18-26	3198-3210	administered	_
18-27	3211-3213	by	_
18-28	3214-3215	a	_
18-29	3216-3223	trained	_
18-30	3224-3235	interviewer	_
18-31	3236-3239	and	_
18-32	3240-3248	reviewed	_
18-33	3249-3251	by	_
18-34	3252-3254	an	_
18-35	3255-3266	experienced	_
18-36	3267-3284	neuropsychologist	_
18-37	3285-3286	,	_
18-38	3287-3289	GM	_
18-39	3290-3291	)	_
18-40	3292-3293	.	_

Text=Other exclusion criteria included contraindications to MRI scanning, having a first-degree relative with present/past history of psychotic disorder, present/past history of use of psychotropic medications, and use of recreational drugs in the two weeks prior to scanning or meeting criteria for substance abuse/dependence by self-report.
19-1	3294-3299	Other	_
19-2	3300-3309	exclusion	_
19-3	3310-3318	criteria	_
19-4	3319-3327	included	_
19-5	3328-3345	contraindications	_
19-6	3346-3348	to	_
19-7	3349-3352	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-8	3353-3361	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-9	3362-3363	,	_
19-10	3364-3370	having	_
19-11	3371-3372	a	_
19-12	3373-3385	first-degree	_
19-13	3386-3394	relative	_
19-14	3395-3399	with	_
19-15	3400-3412	present/past	_
19-16	3413-3420	history	_
19-17	3421-3423	of	_
19-18	3424-3433	psychotic	_
19-19	3434-3442	disorder	_
19-20	3443-3444	,	_
19-21	3445-3457	present/past	_
19-22	3458-3465	history	_
19-23	3466-3468	of	_
19-24	3469-3472	use	_
19-25	3473-3475	of	_
19-26	3476-3488	psychotropic	_
19-27	3489-3500	medications	_
19-28	3501-3502	,	_
19-29	3503-3506	and	_
19-30	3507-3510	use	_
19-31	3511-3513	of	_
19-32	3514-3526	recreational	_
19-33	3527-3532	drugs	_
19-34	3533-3535	in	_
19-35	3536-3539	the	_
19-36	3540-3543	two	_
19-37	3544-3549	weeks	_
19-38	3550-3555	prior	_
19-39	3556-3558	to	_
19-40	3559-3567	scanning	_
19-41	3568-3570	or	_
19-42	3571-3578	meeting	_
19-43	3579-3587	criteria	_
19-44	3588-3591	for	_
19-45	3592-3601	substance	_
19-46	3602-3618	abuse/dependence	_
19-47	3619-3621	by	_
19-48	3622-3633	self-report	_
19-49	3634-3635	.	_

Text=The final sample included 20 participants in both the HS (10 males; age range 18–39 years, M = 26.35, SD = 5.47) and LS groups (11 males; age range 18–44 years, M = 26.70, SD = 7.06).
20-1	3636-3639	The	_
20-2	3640-3645	final	_
20-3	3646-3652	sample	_
20-4	3653-3661	included	_
20-5	3662-3664	20	_
20-6	3665-3677	participants	_
20-7	3678-3680	in	_
20-8	3681-3685	both	_
20-9	3686-3689	the	_
20-10	3690-3692	HS	http://maven.renci.org/NeuroBridge/neurobridge#BiochemicalAssay
20-11	3693-3694	(	_
20-12	3695-3697	10	_
20-13	3698-3703	males	_
20-14	3704-3705	;	_
20-15	3706-3709	age	_
20-16	3710-3715	range	_
20-17	3716-3721	18–39	_
20-18	3722-3727	years	_
20-19	3728-3729	,	_
20-20	3730-3731	M	_
20-21	3732-3733	=	_
20-22	3734-3739	26.35	_
20-23	3740-3741	,	_
20-24	3742-3744	SD	_
20-25	3745-3746	=	_
20-26	3747-3751	5.47	_
20-27	3752-3753	)	_
20-28	3754-3757	and	_
20-29	3758-3760	LS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-30	3761-3767	groups	_
20-31	3768-3769	(	_
20-32	3770-3772	11	_
20-33	3773-3778	males	_
20-34	3779-3780	;	_
20-35	3781-3784	age	_
20-36	3785-3790	range	_
20-37	3791-3796	18–44	_
20-38	3797-3802	years	_
20-39	3803-3804	,	_
20-40	3805-3806	M	_
20-41	3807-3808	=	_
20-42	3809-3814	26.70	_
20-43	3815-3816	,	_
20-44	3817-3819	SD	_
20-45	3820-3821	=	_
20-46	3822-3826	7.06	_
20-47	3827-3828	)	_
20-48	3829-3830	.	_

Text=Three studies have reported previous findings from overlapping sub-samples of this cohort with other imaging modalities.
21-1	3831-3836	Three	_
21-2	3837-3844	studies	_
21-3	3845-3849	have	_
21-4	3850-3858	reported	_
21-5	3859-3867	previous	_
21-6	3868-3876	findings	_
21-7	3877-3881	from	_
21-8	3882-3893	overlapping	_
21-9	3894-3905	sub-samples	_
21-10	3906-3908	of	_
21-11	3909-3913	this	_
21-12	3914-3920	cohort	_
21-13	3921-3925	with	_
21-14	3926-3931	other	_
21-15	3932-3939	imaging	_
21-16	3940-3950	modalities	_
21-17	3951-3952	.	_

Text=Ethical approval for the study was obtained from the KCL College Research Ethics Committee (CREC) and all participants provided written informed consent before initiating any study procedures.
22-1	3953-3960	Ethical	_
22-2	3961-3969	approval	_
22-3	3970-3973	for	_
22-4	3974-3977	the	_
22-5	3978-3983	study	_
22-6	3984-3987	was	_
22-7	3988-3996	obtained	_
22-8	3997-4001	from	_
22-9	4002-4005	the	_
22-10	4006-4009	KCL	_
22-11	4010-4017	College	_
22-12	4018-4026	Research	_
22-13	4027-4033	Ethics	_
22-14	4034-4043	Committee	_
22-15	4044-4045	(	_
22-16	4046-4050	CREC	_
22-17	4051-4052	)	_
22-18	4053-4056	and	_
22-19	4057-4060	all	_
22-20	4061-4073	participants	_
22-21	4074-4082	provided	_
22-22	4083-4090	written	_
22-23	4091-4099	informed	_
22-24	4100-4107	consent	_
22-25	4108-4114	before	_
22-26	4115-4125	initiating	_
22-27	4126-4129	any	_
22-28	4130-4135	study	_
22-29	4136-4146	procedures	_
22-30	4147-4148	.	_

Text=Behavioral assessments On the day of scanning, before scanning commenced, participants completed a semi-structured interview adapted from the Early Psychosis Prevention and Intervention Centre (EPPIC) Drug and Alcohol Assessment Schedule (http: //www.eppic.org.au) to assess current/past medication use and current/past use of alcohol, tobacco and cannabis; the Social Function Questionnaire (SFQ) to measure social functioning; and a validated short version of the Wechsler Adult Intelligence Scale-III (WAIS- III) to measure intellectual ability.
23-1	4149-4159	Behavioral	_
23-2	4160-4171	assessments	_
23-3	4172-4174	On	_
23-4	4175-4178	the	_
23-5	4179-4182	day	_
23-6	4183-4185	of	_
23-7	4186-4194	scanning	_
23-8	4195-4196	,	_
23-9	4197-4203	before	_
23-10	4204-4212	scanning	_
23-11	4213-4222	commenced	_
23-12	4223-4224	,	_
23-13	4225-4237	participants	_
23-14	4238-4247	completed	_
23-15	4248-4249	a	_
23-16	4250-4265	semi-structured	_
23-17	4266-4275	interview	_
23-18	4276-4283	adapted	_
23-19	4284-4288	from	_
23-20	4289-4292	the	_
23-21	4293-4298	Early	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-22	4299-4308	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-23	4309-4319	Prevention	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-24	4320-4323	and	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-25	4324-4336	Intervention	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-26	4337-4343	Centre	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
23-27	4344-4345	(	_
23-28	4346-4351	EPPIC	_
23-29	4352-4353	)	_
23-30	4354-4358	Drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
23-31	4359-4362	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
23-32	4363-4370	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
23-33	4371-4381	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
23-34	4382-4390	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
23-35	4391-4392	(	_
23-36	4393-4397	http	_
23-37	4398-4399	:	_
23-38	4400-4418	//www.eppic.org.au	_
23-39	4419-4420	)	_
23-40	4421-4423	to	_
23-41	4424-4430	assess	_
23-42	4431-4443	current/past	_
23-43	4444-4454	medication	_
23-44	4455-4458	use	_
23-45	4459-4462	and	_
23-46	4463-4475	current/past	_
23-47	4476-4479	use	_
23-48	4480-4482	of	_
23-49	4483-4490	alcohol	_
23-50	4491-4492	,	_
23-51	4493-4500	tobacco	_
23-52	4501-4504	and	_
23-53	4505-4513	cannabis	_
23-54	4514-4515	;	_
23-55	4516-4519	the	_
23-56	4520-4526	Social	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-57	4527-4535	Function	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-58	4536-4549	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-59	4550-4551	(	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-60	4552-4555	SFQ	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-61	4556-4557	)	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
23-62	4558-4560	to	_
23-63	4561-4568	measure	_
23-64	4569-4575	social	_
23-65	4576-4587	functioning	_
23-66	4588-4589	;	_
23-67	4590-4593	and	_
23-68	4594-4595	a	_
23-69	4596-4605	validated	_
23-70	4606-4611	short	_
23-71	4612-4619	version	_
23-72	4620-4622	of	_
23-73	4623-4626	the	_
23-74	4627-4635	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-75	4636-4641	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-76	4642-4654	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-77	4655-4664	Scale-III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-78	4665-4666	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-79	4667-4672	WAIS-	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-80	4673-4676	III	_
23-81	4677-4678	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-82	4679-4681	to	_
23-83	4682-4689	measure	_
23-84	4690-4702	intellectual	_
23-85	4703-4710	ability	_
23-86	4711-4712	.	_

Text=Analysis of demographic and questionnaire data was performed in SPSS 24 (https: //www.ibm.com/analytics/us/en/technology/spss/), with the effect of group being tested using independent sample t-tests for parametric data and χ2-tests for non-parametric data (significance threshold p <.05).
24-1	4713-4721	Analysis	_
24-2	4722-4724	of	_
24-3	4725-4736	demographic	_
24-4	4737-4740	and	_
24-5	4741-4754	questionnaire	_
24-6	4755-4759	data	_
24-7	4760-4763	was	_
24-8	4764-4773	performed	_
24-9	4774-4776	in	_
24-10	4777-4781	SPSS	_
24-11	4782-4784	24	_
24-12	4785-4786	(	_
24-13	4787-4792	https	_
24-14	4793-4794	:	_
24-15	4795-4841	//www.ibm.com/analytics/us/en/technology/spss/	_
24-16	4842-4843	)	_
24-17	4844-4845	,	_
24-18	4846-4850	with	_
24-19	4851-4854	the	_
24-20	4855-4861	effect	_
24-21	4862-4864	of	_
24-22	4865-4870	group	_
24-23	4871-4876	being	_
24-24	4877-4883	tested	_
24-25	4884-4889	using	_
24-26	4890-4901	independent	_
24-27	4902-4908	sample	_
24-28	4909-4916	t-tests	_
24-29	4917-4920	for	_
24-30	4921-4931	parametric	_
24-31	4932-4936	data	_
24-32	4937-4940	and	_
24-33	4941-4949	χ2-tests	_
24-34	4950-4953	for	_
24-35	4954-4968	non-parametric	_
24-36	4969-4973	data	_
24-37	4974-4975	(	_
24-38	4976-4988	significance	_
24-39	4989-4998	threshold	_
24-40	4999-5000	p	_
24-41	5001-5002	<	_
24-42	5003-5006	.05	_
24-43	5007-5008	)	_
24-44	5009-5010	.	_

Text=Imaging acquisition Scanning was performed on a General Electric Discovery MR750 3 T system (Milwaukee, WI, USA) at the Institute of Psychiatry, Psychology & Neuroscience, King's College London.
25-1	5011-5018	Imaging	_
25-2	5019-5030	acquisition	_
25-3	5031-5039	Scanning	_
25-4	5040-5043	was	_
25-5	5044-5053	performed	_
25-6	5054-5056	on	_
25-7	5057-5058	a	_
25-8	5059-5066	General	_
25-9	5067-5075	Electric	_
25-10	5076-5085	Discovery	_
25-11	5086-5091	MR750	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-12	5092-5093	3	_
25-13	5094-5095	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
25-14	5096-5102	system	_
25-15	5103-5104	(	_
25-16	5105-5114	Milwaukee	_
25-17	5115-5116	,	_
25-18	5117-5119	WI	_
25-19	5120-5121	,	_
25-20	5122-5125	USA	_
25-21	5126-5127	)	_
25-22	5128-5130	at	_
25-23	5131-5134	the	_
25-24	5135-5144	Institute	_
25-25	5145-5147	of	_
25-26	5148-5158	Psychiatry	_
25-27	5159-5160	,	_
25-28	5161-5171	Psychology	_
25-29	5172-5173	&	_
25-30	5174-5186	Neuroscience	_
25-31	5187-5188	,	_
25-32	5189-5193	King	_
25-33	5194-5196	's	_
25-34	5197-5204	College	_
25-35	5205-5211	London	_
25-36	5212-5213	.	_

Text=For the rs-fMRI, participants were asked to lie still with their eyes open, and to think of nothing in particular while a fixation cross was displayed in the center of a screen which they viewed through a mirror system.
26-1	5214-5217	For	_
26-2	5218-5221	the	_
26-3	5222-5229	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
26-4	5230-5231	,	_
26-5	5232-5244	participants	_
26-6	5245-5249	were	_
26-7	5250-5255	asked	_
26-8	5256-5258	to	_
26-9	5259-5262	lie	_
26-10	5263-5268	still	_
26-11	5269-5273	with	_
26-12	5274-5279	their	_
26-13	5280-5284	eyes	_
26-14	5285-5289	open	_
26-15	5290-5291	,	_
26-16	5292-5295	and	_
26-17	5296-5298	to	_
26-18	5299-5304	think	_
26-19	5305-5307	of	_
26-20	5308-5315	nothing	_
26-21	5316-5318	in	_
26-22	5319-5329	particular	_
26-23	5330-5335	while	_
26-24	5336-5337	a	_
26-25	5338-5346	fixation	_
26-26	5347-5352	cross	_
26-27	5353-5356	was	_
26-28	5357-5366	displayed	_
26-29	5367-5369	in	_
26-30	5370-5373	the	_
26-31	5374-5380	center	_
26-32	5381-5383	of	_
26-33	5384-5385	a	_
26-34	5386-5392	screen	_
26-35	5393-5398	which	_
26-36	5399-5403	they	_
26-37	5404-5410	viewed	_
26-38	5411-5418	through	_
26-39	5419-5420	a	_
26-40	5421-5427	mirror	_
26-41	5428-5434	system	_
26-42	5435-5436	.	_

Text=Scanning time for the rs-fMRI was 12 min.
27-1	5437-5445	Scanning	_
27-2	5446-5450	time	_
27-3	5451-5454	for	_
27-4	5455-5458	the	_
27-5	5459-5466	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-6	5467-5470	was	_
27-7	5471-5473	12	_
27-8	5474-5477	min	_
27-9	5478-5479	.	_

Text=During this time, ME-EPI images sensitive to BOLD contrast were acquired to measure hemodynamic responses (repetition time: 2500 ms; echo times, 12, 28, 44, 60 ms; flip angle, 80°; 4.0 × 4.0 × 3.0-mm voxels; field of view, 240; 32 axial sections collected with sequential (top down) acquisition and 1-mm interslice gap).
28-1	5480-5486	During	_
28-2	5487-5491	this	_
28-3	5492-5496	time	_
28-4	5497-5498	,	_
28-5	5499-5505	ME-EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
28-6	5506-5512	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
28-7	5513-5522	sensitive	_
28-8	5523-5525	to	_
28-9	5526-5530	BOLD	_
28-10	5531-5539	contrast	_
28-11	5540-5544	were	_
28-12	5545-5553	acquired	_
28-13	5554-5556	to	_
28-14	5557-5564	measure	_
28-15	5565-5576	hemodynamic	_
28-16	5577-5586	responses	_
28-17	5587-5588	(	_
28-18	5589-5599	repetition	_
28-19	5600-5604	time	_
28-20	5605-5606	:	_
28-21	5607-5611	2500	_
28-22	5612-5614	ms	_
28-23	5615-5616	;	_
28-24	5617-5621	echo	_
28-25	5622-5627	times	_
28-26	5628-5629	,	_
28-27	5630-5632	12	_
28-28	5633-5634	,	_
28-29	5635-5637	28	_
28-30	5638-5639	,	_
28-31	5640-5642	44	_
28-32	5643-5644	,	_
28-33	5645-5647	60	_
28-34	5648-5650	ms	_
28-35	5651-5652	;	_
28-36	5653-5657	flip	_
28-37	5658-5663	angle	_
28-38	5664-5665	,	_
28-39	5666-5669	80°	_
28-40	5670-5671	;	_
28-41	5672-5675	4.0	_
28-42	5676-5677	×	_
28-43	5678-5681	4.0	_
28-44	5682-5683	×	_
28-45	5684-5690	3.0-mm	_
28-46	5691-5697	voxels	_
28-47	5698-5699	;	_
28-48	5700-5705	field	_
28-49	5706-5708	of	_
28-50	5709-5713	view	_
28-51	5714-5715	,	_
28-52	5716-5719	240	_
28-53	5720-5721	;	_
28-54	5722-5724	32	_
28-55	5725-5730	axial	_
28-56	5731-5739	sections	_
28-57	5740-5749	collected	_
28-58	5750-5754	with	_
28-59	5755-5765	sequential	_
28-60	5766-5767	(	_
28-61	5768-5771	top	_
28-62	5772-5776	down	_
28-63	5777-5778	)	_
28-64	5779-5790	acquisition	_
28-65	5791-5794	and	_
28-66	5795-5799	1-mm	_
28-67	5800-5810	interslice	_
28-68	5811-5814	gap	_
28-69	5815-5816	)	_
28-70	5817-5818	.	_

Text=A structural scan was acquired for co-registration of the ME-EPI data by means of a three-dimensional T1-weighted inversion recovery-prepared gradient echo sequence (voxel size: 1.05 × 1.05 × 1.2 mm, field of view: 270 mm, 196 slices, repetition time: 7.3 ms, echo time: 3.0 ms, inversion time: 400 ms).
29-1	5819-5820	A	_
29-2	5821-5831	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
29-3	5832-5836	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
29-4	5837-5840	was	_
29-5	5841-5849	acquired	_
29-6	5850-5853	for	_
29-7	5854-5869	co-registration	_
29-8	5870-5872	of	_
29-9	5873-5876	the	_
29-10	5877-5883	ME-EPI	_
29-11	5884-5888	data	_
29-12	5889-5891	by	_
29-13	5892-5897	means	_
29-14	5898-5900	of	_
29-15	5901-5902	a	_
29-16	5903-5920	three-dimensional	_
29-17	5921-5932	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
29-18	5933-5942	inversion	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
29-19	5943-5960	recovery-prepared	_
29-20	5961-5969	gradient	_
29-21	5970-5974	echo	_
29-22	5975-5983	sequence	_
29-23	5984-5985	(	_
29-24	5986-5991	voxel	_
29-25	5992-5996	size	_
29-26	5997-5998	:	_
29-27	5999-6003	1.05	_
29-28	6004-6005	×	_
29-29	6006-6010	1.05	_
29-30	6011-6012	×	_
29-31	6013-6016	1.2	_
29-32	6017-6019	mm	_
29-33	6020-6021	,	_
29-34	6022-6027	field	_
29-35	6028-6030	of	_
29-36	6031-6035	view	_
29-37	6036-6037	:	_
29-38	6038-6041	270	_
29-39	6042-6044	mm	_
29-40	6045-6046	,	_
29-41	6047-6050	196	_
29-42	6051-6057	slices	_
29-43	6058-6059	,	_
29-44	6060-6070	repetition	_
29-45	6071-6075	time	_
29-46	6076-6077	:	_
29-47	6078-6081	7.3	_
29-48	6082-6084	ms	_
29-49	6085-6086	,	_
29-50	6087-6091	echo	_
29-51	6092-6096	time	_
29-52	6097-6098	:	_
29-53	6099-6102	3.0	_
29-54	6103-6105	ms	_
29-55	6106-6107	,	_
29-56	6108-6117	inversion	_
29-57	6118-6122	time	_
29-58	6123-6124	:	_
29-59	6125-6128	400	_
29-60	6129-6131	ms	_
29-61	6132-6133	)	_
29-62	6134-6135	.	_

Text=Imaging preprocessing After resetting of the origins for both T1-weighted and ME-EP images, a study specific template was created using Advanced Normalization Tools (ANTs; http: //stnava.github.io/ANTs/) for later normalization, in order to reduce localization error and improve sensitivity.
30-1	6136-6143	Imaging	_
30-2	6144-6157	preprocessing	_
30-3	6158-6163	After	_
30-4	6164-6173	resetting	_
30-5	6174-6176	of	_
30-6	6177-6180	the	_
30-7	6181-6188	origins	_
30-8	6189-6192	for	_
30-9	6193-6197	both	_
30-10	6198-6209	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-11	6210-6213	and	_
30-12	6214-6219	ME-EP	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-13	6220-6226	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-14	6227-6228	,	_
30-15	6229-6230	a	_
30-16	6231-6236	study	_
30-17	6237-6245	specific	_
30-18	6246-6254	template	_
30-19	6255-6258	was	_
30-20	6259-6266	created	_
30-21	6267-6272	using	_
30-22	6273-6281	Advanced	_
30-23	6282-6295	Normalization	_
30-24	6296-6301	Tools	_
30-25	6302-6303	(	_
30-26	6304-6308	ANTs	_
30-27	6309-6310	;	_
30-28	6311-6315	http	_
30-29	6316-6317	:	_
30-30	6318-6342	//stnava.github.io/ANTs/	_
30-31	6343-6344	)	_
30-32	6345-6348	for	_
30-33	6349-6354	later	_
30-34	6355-6368	normalization	_
30-35	6369-6370	,	_
30-36	6371-6373	in	_
30-37	6374-6379	order	_
30-38	6380-6382	to	_
30-39	6383-6389	reduce	_
30-40	6390-6402	localization	_
30-41	6403-6408	error	_
30-42	6409-6412	and	_
30-43	6413-6420	improve	_
30-44	6421-6432	sensitivity	_
30-45	6433-6434	.	_

Text=One subject from the HS group had to be excluded because of atypical anatomy which undermined the template quality, resulting in a final sample of 20 LS and 19 HS subjects.
31-1	6435-6438	One	_
31-2	6439-6446	subject	_
31-3	6447-6451	from	_
31-4	6452-6455	the	_
31-5	6456-6458	HS	_
31-6	6459-6464	group	_
31-7	6465-6468	had	_
31-8	6469-6471	to	_
31-9	6472-6474	be	_
31-10	6475-6483	excluded	_
31-11	6484-6491	because	_
31-12	6492-6494	of	_
31-13	6495-6503	atypical	_
31-14	6504-6511	anatomy	_
31-15	6512-6517	which	_
31-16	6518-6528	undermined	_
31-17	6529-6532	the	_
31-18	6533-6541	template	_
31-19	6542-6549	quality	_
31-20	6550-6551	,	_
31-21	6552-6561	resulting	_
31-22	6562-6564	in	_
31-23	6565-6566	a	_
31-24	6567-6572	final	_
31-25	6573-6579	sample	_
31-26	6580-6582	of	_
31-27	6583-6585	20	_
31-28	6586-6588	LS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-29	6589-6592	and	_
31-30	6593-6595	19	_
31-31	6596-6598	HS	http://maven.renci.org/NeuroBridge/neurobridge#BiochemicalAssay
31-32	6599-6607	subjects	_
31-33	6608-6609	.	_

Text=The ME-EPI echoes were separated into four distinct time series (corresponding to the four individual echoes), which were then de-spiked using 3dDespike in the Analysis of Functional NeuroImages (AFNI) framework (https: //afni.nimh.nih.gov), and slice time corrected using SPM12 (http: //www.fil.ion.ucl.ac.uk/spm/software/spm12/).
32-1	6610-6613	The	_
32-2	6614-6620	ME-EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-3	6621-6627	echoes	_
32-4	6628-6632	were	_
32-5	6633-6642	separated	_
32-6	6643-6647	into	_
32-7	6648-6652	four	_
32-8	6653-6661	distinct	_
32-9	6662-6666	time	_
32-10	6667-6673	series	_
32-11	6674-6675	(	_
32-12	6676-6689	corresponding	_
32-13	6690-6692	to	_
32-14	6693-6696	the	_
32-15	6697-6701	four	_
32-16	6702-6712	individual	_
32-17	6713-6719	echoes	_
32-18	6720-6721	)	_
32-19	6722-6723	,	_
32-20	6724-6729	which	_
32-21	6730-6734	were	_
32-22	6735-6739	then	_
32-23	6740-6749	de-spiked	_
32-24	6750-6755	using	_
32-25	6756-6765	3dDespike	_
32-26	6766-6768	in	_
32-27	6769-6772	the	_
32-28	6773-6781	Analysis	_
32-29	6782-6784	of	_
32-30	6785-6795	Functional	_
32-31	6796-6807	NeuroImages	_
32-32	6808-6809	(	_
32-33	6810-6814	AFNI	_
32-34	6815-6816	)	_
32-35	6817-6826	framework	_
32-36	6827-6828	(	_
32-37	6829-6834	https	_
32-38	6835-6836	:	_
32-39	6837-6856	//afni.nimh.nih.gov	_
32-40	6857-6858	)	_
32-41	6859-6860	,	_
32-42	6861-6864	and	_
32-43	6865-6870	slice	_
32-44	6871-6875	time	_
32-45	6876-6885	corrected	_
32-46	6886-6891	using	_
32-47	6892-6897	SPM12	_
32-48	6898-6899	(	_
32-49	6900-6904	http	_
32-50	6905-6906	:	_
32-51	6907-6950	//www.fil.ion.ucl.ac.uk/spm/software/spm12/	_
32-52	6951-6952	)	_
32-53	6953-6954	.	_

Text=Parameters for motion correction were estimated from the first echo, and applied to all four echoes using FSL's mcFLIRT.
33-1	6955-6965	Parameters	_
33-2	6966-6969	for	_
33-3	6970-6976	motion	_
33-4	6977-6987	correction	_
33-5	6988-6992	were	_
33-6	6993-7002	estimated	_
33-7	7003-7007	from	_
33-8	7008-7011	the	_
33-9	7012-7017	first	_
33-10	7018-7022	echo	_
33-11	7023-7024	,	_
33-12	7025-7028	and	_
33-13	7029-7036	applied	_
33-14	7037-7039	to	_
33-15	7040-7043	all	_
33-16	7044-7048	four	_
33-17	7049-7055	echoes	_
33-18	7056-7061	using	_
33-19	7062-7065	FSL	_
33-20	7066-7068	's	_
33-21	7069-7076	mcFLIRT	_
33-22	7077-7078	.	_

Text=Subjects' ME-EP images were then co-registered to the T1 scan using boundary-based registration as implemented in FLIRT.
34-1	7079-7087	Subjects	_
34-2	7088-7089	'	_
34-3	7090-7095	ME-EP	_
34-4	7096-7102	images	_
34-5	7103-7107	were	_
34-6	7108-7112	then	_
34-7	7113-7126	co-registered	_
34-8	7127-7129	to	_
34-9	7130-7133	the	_
34-10	7134-7136	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-11	7137-7141	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-12	7142-7147	using	_
34-13	7148-7162	boundary-based	_
34-14	7163-7175	registration	_
34-15	7176-7178	as	_
34-16	7179-7190	implemented	_
34-17	7191-7193	in	_
34-18	7194-7199	FLIRT	_
34-19	7200-7201	.	_

Text=Again, parameters were estimated for the first echo, and subsequently applied to all four echoes.
35-1	7202-7207	Again	_
35-2	7208-7209	,	_
35-3	7210-7220	parameters	_
35-4	7221-7225	were	_
35-5	7226-7235	estimated	_
35-6	7236-7239	for	_
35-7	7240-7243	the	_
35-8	7244-7249	first	_
35-9	7250-7254	echo	_
35-10	7255-7256	,	_
35-11	7257-7260	and	_
35-12	7261-7273	subsequently	_
35-13	7274-7281	applied	_
35-14	7282-7284	to	_
35-15	7285-7288	all	_
35-16	7289-7293	four	_
35-17	7294-7300	echoes	_
35-18	7301-7302	.	_

Text=All echoes were spatially normalized to the study-specific template, and from there to Montreal Neurological Institute (MNI) space.
36-1	7303-7306	All	_
36-2	7307-7313	echoes	_
36-3	7314-7318	were	_
36-4	7319-7328	spatially	_
36-5	7329-7339	normalized	_
36-6	7340-7342	to	_
36-7	7343-7346	the	_
36-8	7347-7361	study-specific	_
36-9	7362-7370	template	_
36-10	7371-7372	,	_
36-11	7373-7376	and	_
36-12	7377-7381	from	_
36-13	7382-7387	there	_
36-14	7388-7390	to	_
36-15	7391-7399	Montreal	_
36-16	7400-7412	Neurological	_
36-17	7413-7422	Institute	_
36-18	7423-7424	(	_
36-19	7425-7428	MNI	_
36-20	7429-7430	)	_
36-21	7431-7436	space	_
36-22	7437-7438	.	_

Text=Finally, the images from all echoes were z-concatenated for further processing, i.e.
37-1	7439-7446	Finally	_
37-2	7447-7448	,	_
37-3	7449-7452	the	_
37-4	7453-7459	images	_
37-5	7460-7464	from	_
37-6	7465-7468	all	_
37-7	7469-7475	echoes	_
37-8	7476-7480	were	_
37-9	7481-7495	z-concatenated	_
37-10	7496-7499	for	_
37-11	7500-7507	further	_
37-12	7508-7518	processing	_
37-13	7519-7520	,	_
37-14	7521-7524	i.e	_
37-15	7525-7526	.	_

Text=the space-by-time matrices from each echo were appended to one another in the z-direction to form a single matrix using the 3dZcat function in AFNI.
38-1	7527-7530	the	_
38-2	7531-7544	space-by-time	_
38-3	7545-7553	matrices	_
38-4	7554-7558	from	_
38-5	7559-7563	each	_
38-6	7564-7568	echo	_
38-7	7569-7573	were	_
38-8	7574-7582	appended	_
38-9	7583-7585	to	_
38-10	7586-7589	one	_
38-11	7590-7597	another	_
38-12	7598-7600	in	_
38-13	7601-7604	the	_
38-14	7605-7616	z-direction	_
38-15	7617-7619	to	_
38-16	7620-7624	form	_
38-17	7625-7626	a	_
38-18	7627-7633	single	_
38-19	7634-7640	matrix	_
38-20	7641-7646	using	_
38-21	7647-7650	the	_
38-22	7651-7657	3dZcat	_
38-23	7658-7666	function	_
38-24	7667-7669	in	_
38-25	7670-7674	AFNI	_
38-26	7675-7676	.	_

Text=TEDANA, a python script that forms part of the Multi Echo Independent Component Analysis (MEICA) package (https: //afni.nimh.nih.gov/pub/dist/src/pkundu/meica.py) was called to perform TE dependent ICA-based denoising and T2 * weighted averaging (optimal combination) of echoes as described above.
39-1	7677-7683	TEDANA	_
39-2	7684-7685	,	_
39-3	7686-7687	a	_
39-4	7688-7694	python	_
39-5	7695-7701	script	_
39-6	7702-7706	that	_
39-7	7707-7712	forms	_
39-8	7713-7717	part	_
39-9	7718-7720	of	_
39-10	7721-7724	the	_
39-11	7725-7730	Multi	_
39-12	7731-7735	Echo	_
39-13	7736-7747	Independent	_
39-14	7748-7757	Component	_
39-15	7758-7766	Analysis	_
39-16	7767-7768	(	_
39-17	7769-7774	MEICA	_
39-18	7775-7776	)	_
39-19	7777-7784	package	_
39-20	7785-7786	(	_
39-21	7787-7792	https	_
39-22	7793-7794	:	_
39-23	7795-7843	//afni.nimh.nih.gov/pub/dist/src/pkundu/meica.py	_
39-24	7844-7845	)	_
39-25	7846-7849	was	_
39-26	7850-7856	called	_
39-27	7857-7859	to	_
39-28	7860-7867	perform	_
39-29	7868-7870	TE	_
39-30	7871-7880	dependent	_
39-31	7881-7890	ICA-based	_
39-32	7891-7900	denoising	_
39-33	7901-7904	and	_
39-34	7905-7907	T2	_
39-35	7908-7909	*	_
39-36	7910-7918	weighted	_
39-37	7919-7928	averaging	_
39-38	7929-7930	(	_
39-39	7931-7938	optimal	_
39-40	7939-7950	combination	_
39-41	7951-7952	)	_
39-42	7953-7955	of	_
39-43	7956-7962	echoes	_
39-44	7963-7965	as	_
39-45	7966-7975	described	_
39-46	7976-7981	above	_
39-47	7982-7983	.	_

Text=The denoised, optimally combined images were subsequently taken forward for motion correction, removal of white matter (WM) and cerebrospinal fluid (CSF) signal via regression, and band-pass-filtering (frequency range 0.08–0.01 Hz).
40-1	7984-7987	The	_
40-2	7988-7996	denoised	_
40-3	7997-7998	,	_
40-4	7999-8008	optimally	_
40-5	8009-8017	combined	_
40-6	8018-8024	images	_
40-7	8025-8029	were	_
40-8	8030-8042	subsequently	_
40-9	8043-8048	taken	_
40-10	8049-8056	forward	_
40-11	8057-8060	for	_
40-12	8061-8067	motion	_
40-13	8068-8078	correction	_
40-14	8079-8080	,	_
40-15	8081-8088	removal	_
40-16	8089-8091	of	_
40-17	8092-8097	white	_
40-18	8098-8104	matter	_
40-19	8105-8106	(	_
40-20	8107-8109	WM	_
40-21	8110-8111	)	_
40-22	8112-8115	and	_
40-23	8116-8129	cerebrospinal	_
40-24	8130-8135	fluid	_
40-25	8136-8137	(	_
40-26	8138-8141	CSF	_
40-27	8142-8143	)	_
40-28	8144-8150	signal	_
40-29	8151-8154	via	_
40-30	8155-8165	regression	_
40-31	8166-8167	,	_
40-32	8168-8171	and	_
40-33	8172-8191	band-pass-filtering	_
40-34	8192-8193	(	_
40-35	8194-8203	frequency	_
40-36	8204-8209	range	_
40-37	8210-8219	0.08–0.01	_
40-38	8220-8222	Hz	_
40-39	8223-8224	)	_
40-40	8225-8226	.	_

Text=A comparison of the mean framewise displacement (FD) between HS and LS subjects revealed no significant difference in head motion between groups (t = 0.358, p = .72).
41-1	8227-8228	A	_
41-2	8229-8239	comparison	_
41-3	8240-8242	of	_
41-4	8243-8246	the	_
41-5	8247-8251	mean	_
41-6	8252-8261	framewise	_
41-7	8262-8274	displacement	_
41-8	8275-8276	(	_
41-9	8277-8279	FD	_
41-10	8280-8281	)	_
41-11	8282-8289	between	_
41-12	8290-8292	HS	_
41-13	8293-8296	and	_
41-14	8297-8299	LS	_
41-15	8300-8308	subjects	_
41-16	8309-8317	revealed	_
41-17	8318-8320	no	_
41-18	8321-8332	significant	_
41-19	8333-8343	difference	_
41-20	8344-8346	in	_
41-21	8347-8351	head	_
41-22	8352-8358	motion	_
41-23	8359-8366	between	_
41-24	8367-8373	groups	_
41-25	8374-8375	(	_
41-26	8376-8377	t	_
41-27	8378-8379	=	_
41-28	8380-8385	0.358	_
41-29	8386-8387	,	_
41-30	8388-8389	p	_
41-31	8390-8391	=	_
41-32	8392-8395	.72	_
41-33	8396-8397	)	_
41-34	8398-8399	.	_

Text=No individual subject showed mean FD in excess of 0.12 mm.
42-1	8400-8402	No	_
42-2	8403-8413	individual	_
42-3	8414-8421	subject	_
42-4	8422-8428	showed	_
42-5	8429-8433	mean	_
42-6	8434-8436	FD	_
42-7	8437-8439	in	_
42-8	8440-8446	excess	_
42-9	8447-8449	of	_
42-10	8450-8454	0.12	_
42-11	8455-8457	mm	_
42-12	8458-8459	.	_

Text=Imaging analysis We defined six bilateral striatal seeds based on previous validated work on striatal connectivity: ventral striatum inferior/nucleus accumbens (VSi; ±9, 9, −8); ventral striatum superior (VSs; ±10, 15, 0); dorsal caudate (DC; ±13, 15, 9); dorsal caudal putamen (DCP; ±28, 1, 3); dorsal rostral putamen (DRP; ±25, 8, 6); and ventral rostral putamen (VRP; ±20, 12, –3) (Fig.
43-1	8460-8467	Imaging	_
43-2	8468-8476	analysis	_
43-3	8477-8479	We	_
43-4	8480-8487	defined	_
43-5	8488-8491	six	_
43-6	8492-8501	bilateral	_
43-7	8502-8510	striatal	_
43-8	8511-8516	seeds	_
43-9	8517-8522	based	_
43-10	8523-8525	on	_
43-11	8526-8534	previous	_
43-12	8535-8544	validated	_
43-13	8545-8549	work	_
43-14	8550-8552	on	_
43-15	8553-8561	striatal	_
43-16	8562-8574	connectivity	_
43-17	8575-8576	:	_
43-18	8577-8584	ventral	_
43-19	8585-8593	striatum	_
43-20	8594-8610	inferior/nucleus	_
43-21	8611-8620	accumbens	_
43-22	8621-8622	(	_
43-23	8623-8626	VSi	_
43-24	8627-8628	;	_
43-25	8629-8631	±9	_
43-26	8632-8633	,	_
43-27	8634-8635	9	_
43-28	8636-8637	,	_
43-29	8638-8640	−8	_
43-30	8641-8642	)	_
43-31	8643-8644	;	_
43-32	8645-8652	ventral	_
43-33	8653-8661	striatum	_
43-34	8662-8670	superior	_
43-35	8671-8672	(	_
43-36	8673-8676	VSs	_
43-37	8677-8678	;	_
43-38	8679-8682	±10	_
43-39	8683-8684	,	_
43-40	8685-8687	15	_
43-41	8688-8689	,	_
43-42	8690-8691	0	_
43-43	8692-8693	)	_
43-44	8694-8695	;	_
43-45	8696-8702	dorsal	_
43-46	8703-8710	caudate	_
43-47	8711-8712	(	_
43-48	8713-8715	DC	_
43-49	8716-8717	;	_
43-50	8718-8721	±13	_
43-51	8722-8723	,	_
43-52	8724-8726	15	_
43-53	8727-8728	,	_
43-54	8729-8730	9	_
43-55	8731-8732	)	_
43-56	8733-8734	;	_
43-57	8735-8741	dorsal	_
43-58	8742-8748	caudal	_
43-59	8749-8756	putamen	_
43-60	8757-8758	(	_
43-61	8759-8762	DCP	_
43-62	8763-8764	;	_
43-63	8765-8768	±28	_
43-64	8769-8770	,	_
43-65	8771-8772	1	_
43-66	8773-8774	,	_
43-67	8775-8776	3	_
43-68	8777-8778	)	_
43-69	8779-8780	;	_
43-70	8781-8787	dorsal	_
43-71	8788-8795	rostral	_
43-72	8796-8803	putamen	_
43-73	8804-8805	(	_
43-74	8806-8809	DRP	_
43-75	8810-8811	;	_
43-76	8812-8815	±25	_
43-77	8816-8817	,	_
43-78	8818-8819	8	_
43-79	8820-8821	,	_
43-80	8822-8823	6	_
43-81	8824-8825	)	_
43-82	8826-8827	;	_
43-83	8828-8831	and	_
43-84	8832-8839	ventral	_
43-85	8840-8847	rostral	_
43-86	8848-8855	putamen	_
43-87	8856-8857	(	_
43-88	8858-8861	VRP	_
43-89	8862-8863	;	_
43-90	8864-8867	±20	_
43-91	8868-8869	,	_
43-92	8870-8872	12	_
43-93	8873-8874	,	_
43-94	8875-8877	–3	_
43-95	8878-8879	)	_
43-96	8880-8881	(	_
43-97	8882-8885	Fig	_
43-98	8886-8887	.	_

Text=2A), with the radius set at 3.5 mm.
44-1	8888-8890	2A	_
44-2	8891-8892	)	_
44-3	8893-8894	,	_
44-4	8895-8899	with	_
44-5	8900-8903	the	_
44-6	8904-8910	radius	_
44-7	8911-8914	set	_
44-8	8915-8917	at	_
44-9	8918-8921	3.5	_
44-10	8922-8924	mm	_
44-11	8925-8926	.	_

Text=The mean signal was extracted from the seed regions (voxel-wise) using the REST toolbox to perform Pearson's correlation coefficients between these regressors and the rest of the brain (voxel-wise), which were subsequently Fisher's Z transformed.
45-1	8927-8930	The	_
45-2	8931-8935	mean	_
45-3	8936-8942	signal	_
45-4	8943-8946	was	_
45-5	8947-8956	extracted	_
45-6	8957-8961	from	_
45-7	8962-8965	the	_
45-8	8966-8970	seed	_
45-9	8971-8978	regions	_
45-10	8979-8980	(	_
45-11	8981-8991	voxel-wise	_
45-12	8992-8993	)	_
45-13	8994-8999	using	_
45-14	9000-9003	the	_
45-15	9004-9008	REST	_
45-16	9009-9016	toolbox	_
45-17	9017-9019	to	_
45-18	9020-9027	perform	_
45-19	9028-9035	Pearson	_
45-20	9036-9038	's	_
45-21	9039-9050	correlation	_
45-22	9051-9063	coefficients	_
45-23	9064-9071	between	_
45-24	9072-9077	these	_
45-25	9078-9088	regressors	_
45-26	9089-9092	and	_
45-27	9093-9096	the	_
45-28	9097-9101	rest	_
45-29	9102-9104	of	_
45-30	9105-9108	the	_
45-31	9109-9114	brain	_
45-32	9115-9116	(	_
45-33	9117-9127	voxel-wise	_
45-34	9128-9129	)	_
45-35	9130-9131	,	_
45-36	9132-9137	which	_
45-37	9138-9142	were	_
45-38	9143-9155	subsequently	_
45-39	9156-9162	Fisher	_
45-40	9163-9165	's	_
45-41	9166-9167	Z	_
45-42	9168-9179	transformed	_
45-43	9180-9181	.	_

Text=The resulting Z-maps were then taken to group-level whole-brain analysis using the General Linear Model as implemented in SPM12.
46-1	9182-9185	The	_
46-2	9186-9195	resulting	_
46-3	9196-9202	Z-maps	_
46-4	9203-9207	were	_
46-5	9208-9212	then	_
46-6	9213-9218	taken	_
46-7	9219-9221	to	_
46-8	9222-9233	group-level	_
46-9	9234-9245	whole-brain	_
46-10	9246-9254	analysis	_
46-11	9255-9260	using	_
46-12	9261-9264	the	_
46-13	9265-9272	General	_
46-14	9273-9279	Linear	_
46-15	9280-9285	Model	_
46-16	9286-9288	as	_
46-17	9289-9300	implemented	_
46-18	9301-9303	in	_
46-19	9304-9309	SPM12	_
46-20	9310-9311	.	_

Text=Connectivity differences between groups were examined using t-contrasts.
47-1	9312-9324	Connectivity	_
47-2	9325-9336	differences	_
47-3	9337-9344	between	_
47-4	9345-9351	groups	_
47-5	9352-9356	were	_
47-6	9357-9365	examined	_
47-7	9366-9371	using	_
47-8	9372-9383	t-contrasts	_
47-9	9384-9385	.	_

Text=We used a cluster forming threshold of p <.001 uncorrected, to then enforce cluster-wise correction for multiple testing at p <.05 family-wise error (FWE) rate, based on previous studies.
48-1	9386-9388	We	_
48-2	9389-9393	used	_
48-3	9394-9395	a	_
48-4	9396-9403	cluster	_
48-5	9404-9411	forming	_
48-6	9412-9421	threshold	_
48-7	9422-9424	of	_
48-8	9425-9426	p	_
48-9	9427-9428	<	_
48-10	9429-9433	.001	_
48-11	9434-9445	uncorrected	_
48-12	9446-9447	,	_
48-13	9448-9450	to	_
48-14	9451-9455	then	_
48-15	9456-9463	enforce	_
48-16	9464-9476	cluster-wise	_
48-17	9477-9487	correction	_
48-18	9488-9491	for	_
48-19	9492-9500	multiple	_
48-20	9501-9508	testing	_
48-21	9509-9511	at	_
48-22	9512-9513	p	_
48-23	9514-9515	<	_
48-24	9516-9519	.05	_
48-25	9520-9531	family-wise	_
48-26	9532-9537	error	_
48-27	9538-9539	(	_
48-28	9540-9543	FWE	_
48-29	9544-9545	)	_
48-30	9546-9550	rate	_
48-31	9551-9552	,	_
48-32	9553-9558	based	_
48-33	9559-9561	on	_
48-34	9562-9570	previous	_
48-35	9571-9578	studies	_
48-36	9579-9580	.	_

Text=Potential effects of age or substance use (alcohol, cigarettes and cannabis) on areas showing significant group differences in connectivity were examined with an additional ANCOVA in SPM.
49-1	9581-9590	Potential	_
49-2	9591-9598	effects	_
49-3	9599-9601	of	_
49-4	9602-9605	age	_
49-5	9606-9608	or	_
49-6	9609-9618	substance	_
49-7	9619-9622	use	_
49-8	9623-9624	(	_
49-9	9625-9632	alcohol	_
49-10	9633-9634	,	_
49-11	9635-9645	cigarettes	_
49-12	9646-9649	and	_
49-13	9650-9658	cannabis	_
49-14	9659-9660	)	_
49-15	9661-9663	on	_
49-16	9664-9669	areas	_
49-17	9670-9677	showing	_
49-18	9678-9689	significant	_
49-19	9690-9695	group	_
49-20	9696-9707	differences	_
49-21	9708-9710	in	_
49-22	9711-9723	connectivity	_
49-23	9724-9728	were	_
49-24	9729-9737	examined	_
49-25	9738-9742	with	_
49-26	9743-9745	an	_
49-27	9746-9756	additional	_
49-28	9757-9763	ANCOVA	_
49-29	9764-9766	in	_
49-30	9767-9770	SPM	_
49-31	9771-9772	.	_

Text=Finally, associations between symptom scores (O-LIFE UE) in HS subjects and Z-scores averaged across clusters showing group differences were analyzed using linear regression in SPSS.
50-1	9773-9780	Finally	_
50-2	9781-9782	,	_
50-3	9783-9795	associations	_
50-4	9796-9803	between	_
50-5	9804-9811	symptom	_
50-6	9812-9818	scores	_
50-7	9819-9820	(	_
50-8	9821-9827	O-LIFE	_
50-9	9828-9830	UE	_
50-10	9831-9832	)	_
50-11	9833-9835	in	_
50-12	9836-9838	HS	_
50-13	9839-9847	subjects	_
50-14	9848-9851	and	_
50-15	9852-9860	Z-scores	_
50-16	9861-9869	averaged	_
50-17	9870-9876	across	_
50-18	9877-9885	clusters	_
50-19	9886-9893	showing	_
50-20	9894-9899	group	_
50-21	9900-9911	differences	_
50-22	9912-9916	were	_
50-23	9917-9925	analyzed	_
50-24	9926-9931	using	_
50-25	9932-9938	linear	_
50-26	9939-9949	regression	_
50-27	9950-9952	in	_
50-28	9953-9957	SPSS	_
50-29	9958-9959	.	_

